{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:30:39Z","timestamp":1788805839272,"version":"build-2803163510"},"reference-count":22,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"crossref","award":["2013089"],"award-info":[{"award-number":["2013089"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"crossref","award":["2015113"],"award-info":[{"award-number":["2015113"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence regarding optimal duration of antibiotic treatment in neuroborreliosis. We aimed to compare efficacy and safety of oral doxycycline for 2 and 6\u2009weeks in European Lyme neuroborreliosis (LNB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The trial had a randomised, double-blinded, placebo-controlled, non-inferiority design. Patients with LNB were recruited from eight Norwegian hospitals and randomised to doxycycline 200\u2009mg once daily for 2\u2009weeks, followed by 4\u2009weeks of placebo, or doxycycline 200\u2009mg once daily for 6\u2009weeks. The primary endpoint was clinical improvement as measured by difference in a Composite Clinical Score (0\u201364 points) from baseline to 6\u2009months. The non-inferiority margin was predetermined to 0.5 points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and twenty-one patients were included. Fifty-two treated for 2\u2009weeks and 53 for 6\u2009weeks were included in the intention-to-treat analyses, and 52 and 51 in per-protocol analysis. Mean difference in clinical improvement between the groups was 0.06, 95%\u2009CI \u22121.2 to 1.2, p=0.99 in the intention-to-treat population, and \u22120.4, 95%\u2009CI \u22121.4 to 0.7, p=0.51 in the per-protocol population and non-inferiority could not be established. There were no treatment failures and no serious adverse events. The groups did not differ in secondary outcomes including clinical scores at 10 weeks and 12 months, cerebrospinal fluid data and patient-reported outcome measures. Patients receiving 6\u2009weeks doxycycline reported slightly more side effects in week 5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results strongly indicate that there are no benefits of doxycycline treatment beyond 2\u2009weeks in European LNB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>2015-001481-25.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-329724","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:59:24Z","timestamp":1658973564000},"page":"1222-1228","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-6287","authenticated-orcid":false,"given":"Anne Marit","family":"Solheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5slaug Rudjord","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audun Olav","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi \u00d8yen","family":"Flemmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synne","family":"Brune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Johanne Nordstr\u00f8m","family":"Forselv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Are Hugo","family":"Pripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margrete Halvorsen","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Eikeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Reiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9160-2805","authenticated-orcid":false,"given":"\u00c5se","family":"Mygland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unn","family":"Lj\u00f8stad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2023051800251947000_93.11.1222.1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1104"},{"key":"2023051800251947000_93.11.1222.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70119-4"},{"key":"2023051800251947000_93.11.1222.3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/cid\/ciaa217","article-title":"Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicenter, equivalence, randomized, open-label trial","volume":"72","author":"Kortela","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023051800251947000_93.11.1222.4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ene.12420","article-title":"Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension","volume":"21","author":"Bremell","year":"2014","journal-title":"Eur J Neurol"},{"key":"2023051800251947000_93.11.1222.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02862.x"},{"key":"2023051800251947000_93.11.1222.6","article-title":"Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis","volume":"18","author":"Rauer","year":"2020","journal-title":"Ger Med Sci"},{"key":"2023051800251947000_93.11.1222.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1261"},{"key":"2023051800251947000_93.11.1222.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0340-2"},{"key":"2023051800251947000_93.11.1222.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505425"},{"key":"2023051800251947000_93.11.1222.10","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000071227.23769.9E"},{"key":"2023051800251947000_93.11.1222.11","doi-asserted-by":"crossref","first-page":"e1447","DOI":"10.1212\/WNL.0000000000007186","article-title":"Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis","volume":"92","author":"Berende","year":"2019","journal-title":"Neurology"},{"key":"2023051800251947000_93.11.1222.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1041"},{"key":"2023051800251947000_93.11.1222.13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00415-017-8559-z","article-title":"Lyme neuroborreliosis: do we treat according to guidelines?","volume":"264","author":"Lorentzen","year":"2017","journal-title":"J Neurol"},{"key":"2023051800251947000_93.11.1222.14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/ene.12744","article-title":"Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review","volume":"22","author":"Dersch","year":"2015","journal-title":"Eur J Neurol"},{"key":"2023051800251947000_93.11.1222.15","first-page":"Cd006978","article-title":"Antibiotics for the neurological complications of Lyme disease","volume":"12","author":"Cadavid","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2023051800251947000_93.11.1222.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027083"},{"key":"2023051800251947000_93.11.1222.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02756.x"},{"key":"2023051800251947000_93.11.1222.18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix568"},{"key":"2023051800251947000_93.11.1222.19","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1111\/ene.14962","article-title":"Clinical manifestations and long\u2010term outcome of early Lyme neuroborreliosis according to the European Federation of neurological societies diagnostic criteria (definite versus possible) in central Europe. A retrospective cohort study","volume":"28","author":"Stupica","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023051800251947000_93.11.1222.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03563.x"},{"key":"2023051800251947000_93.11.1222.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01799.x"},{"key":"2023051800251947000_93.11.1222.22","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.989837"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-329724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T03:25:51Z","timestamp":1684380351000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-329724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,14]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jnnp-2022-329724"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-329724","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}